Taysha Gene Therapies Past Earnings Performance
Past criteria checks 0/6
Taysha Gene Therapies's earnings have been declining at an average annual rate of -24.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 133.6% per year.
Key information
-24.4%
Earnings growth rate
0.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 133.6% |
| Return on equity | -148.9% |
| Net Margin | -722.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13Taysha teams up with AllStripes to advance gene therapy in rare disorder
Jan 04Revenue & Expenses BreakdownBeta
How Taysha Gene Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15 | -112 | 30 | 57 |
| 30 Sep 23 | 14 | -214 | 30 | 54 |
| 30 Jun 23 | 10 | -124 | 30 | 59 |
| 31 Mar 23 | 7 | -133 | 34 | 63 |
| 31 Dec 22 | 3 | -166 | 37 | 91 |
| 30 Sep 22 | 0 | -161 | 42 | 116 |
| 30 Jun 22 | 0 | -186 | 44 | 139 |
| 31 Mar 22 | 0 | -193 | 45 | 146 |
| 31 Dec 21 | 0 | -175 | 41 | 132 |
| 30 Sep 21 | 0 | -142 | 36 | 106 |
| 30 Jun 21 | 0 | -106 | 28 | 78 |
| 31 Mar 21 | 0 | -87 | 19 | 50 |
| 31 Dec 20 | 0 | -60 | 11 | 32 |
Quality Earnings: TSHA is currently unprofitable.
Growing Profit Margin: TSHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSHA is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare TSHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TSHA has a negative Return on Equity (-148.88%), as it is currently unprofitable.